doi: 10.1111/j.1744-313X.2012.01115.x 93 SheaPRIshwadCSBunkerCHPatrickALKullerLHFerrellRE
Neither were published and Pliva was so excited about the results it abandoned the drug entirely One Phase I safety and pharmacokinetics trial of oral BPC-157, registered in 2015, that has no public results and appears to have been withdrawn or abandoned Three small and nonrandomized uncontrolled pilot studies from a single for-profit clinic in Florida, which included a 16-patient knee-pain chart review, a 12-woman interstitial cystitis study, and a small intravenous safety study One legitimate entry: a registered Phase 2 trial of BPC-157 for acute hamstring strain
Muscle Injury: In rat muscle transection and crush injury models, BPC-157 treatment improved muscle structure, function, and biomechanics, including improved load to failure, motor function indices, and reduced atrophy
Apart from musculoskeletal and gastrointestinal investigations, BPC-157 has also been used in research involving the nervous system
Potential benefits may include: BPC 157 may assist the bodys natural healing response in muscles, tendons, and ligaments by encouraging cellular repair and regeneration
Week 48 What you may notice: Measurable reduction in body fat
